- All Journals
- Al-Qadisiyah University
- Basrah University
- Kirkuk University
- Mosul University
- The Iraqi Borad for Medical Specialization
- University of Anbar
- University of Technology
- Al Mustafa University
- Al-Zahraa University for Women
- Alnoor University
- Kunooz University
- Misan University
- Ninevah University
- Tikrit University
- University of Al-Hamdaniya
- University of Kerbala
Effects of atorvastatin on some inflammatory markers in patients with multiple sclerosis treated by interferon beta-1b | ||
| Iraqi Journal of Pharmacy | ||
| Article 4, Volume 14, Issue 1, 2014, Pages 23-31 PDF (317.46 K) | ||
| Document Type: Research Paper | ||
| DOI: 10.33899/iphr.2019.161191 | ||
| Authors | ||
| Farah Waleed Mahmood1; Shamil Hashim Othman2 | ||
| 1Ibn-Siena Teaching Hospital, Nineveh Health Directorate, Ministry of Health ,Iraq | ||
| 2Department of pharmacology, College of Medicine, University of Mosul,Mosul, Iraq | ||
| Abstract | ||
| Objective: To investigate the effect of Atorvastatin vs. placebo on some inflammatory markers in patients with multiple sclerosis treated by interferone beta-1b.To achieve the aim of this study, a randomized control comparative trial was adopted. Patients and Methods: A total of 100 patients with multiple sclerosis were recruited and investigated for some inflammatory markers which included, interleukin-2, tumor necrosis factor-α, C-reactive protein, and erythrocyte sedimentation rate. The patients were divided into 2 groups, namely the atorvastatin group which consisted of 50 patients and the placebo group which consisted of 50 patients. The patient groups were followed- up for 12 weeks during which the above parameters were measured before starting therapies and at the end of the follow-up period using commercially available kits. The patient groups were compared with the control group consisted of 50 apparently healthy subjects. Results: The IL-2,TNF-α,CRP and ESR at baseline in both patient groups were found significantly elevated as compared with the control group ( p< 0.001) . The use of atorvastatinhas resulted in significant decrease on the above parameters with non-significant effects in the placebogroup. Atorvastatinappeared to be superior in compared with the placebo group. Conclusion: The use of atorvastatinfor 12 weeks in patients withmultiple sclerosis treated by interferone-beta has beneficial effect on some inflammatory markers studied in this research( IL-2,TNF-α,CRP and ESR). | ||
| Keywords | ||
| Multiple sclerosis; Atorvastatin; Interferone-beta-1b | ||
|
Statistics Article View: 543 PDF Download: 354 |
||